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Mean platelet volume as a marker of future cardiovascular
disease risk in pregnant women with impaired fasting glucose
and impaired glucose tolerance
Nermin KÖŞÜŞ, Aydın KÖŞÜŞ, Nilgün TURHAN

Aim: To compare the mean platelet volume (MPV) of pregnant women with mild glycemic disorders with that of healthy
pregnant women to find whether these disorders are risk factors for future cardiovascular disease.
Materials and methods: Fasting blood glucose and 50-g oral glucose loading were measured. A 100-g, 3-h oral glucose
tolerance test was done when plasma glucose was ≥140 mg/dL, following a loading test. According to the test results, 4
groups were formed: control, impaired fasting glucose, false positive loading test, and impaired glucose tolerance. The
hematologic parameters were compared in all of the groups.
Results: The mean MPV of the control group was lower than those of the other groups. The MPV had high sensitivity in
prediction of the false positive loading test (sensitivity: 70.0%, specificity: 55.2%, AUC = 0.602, P = 0.029) and impaired
glucose tolerance (sensitivity: 73.1%, specificity: 46.1%, AUC = 0.621, P = 0.009), although its sensitivity was lower than the
others in prediction of impaired fasting glucose (sensitivity: 60.7%, specificity: 58.2%, AUC = 0.558, P = 0.374).
Conclusion: Mild glycemic disorders are associated with increased MPV. Increased MPV might be associated with elevated
baseline cardiovascular risk factors. Individuals with these glycemic disorders might be more aggressively targeted with
strategies to lower cardiovascular disease risk.
Key words: Impaired glucose tolerance, impaired fasting glucose, mean platelet volume, cardiovascular disease risk,
pregnancy

Bozulmuş açlık glukozu ve bozulmuş glukoz toleransı olan gebe kadınlarda
gelecekteki kardiyovasküler hastalık risk belirteci olarak ortalama trombosit hacmi
Amaç: Amacımız hafif glisemik bozukluğu olan gebelerle sağlıklı gebelerin ortalama platelet hacmi (MPV) kıyaslanarak,
bu glisemik bozuklukların, gelecekte oluşabilecek kardiovasküler hastalık açısından risk taşıyıp taşımadığını tespit etmekti.
Yöntem ve gereç: Hastaların açlık kan şekeri ölçüldü ve hepsine 50 g oral glukoz yükleme testi yapıldı. Yükleme sonrası
sonrası plasma glukozu ≥140 mg/dL ölçülenlere 100-g 3-saatlik oral glukoz tolerans testi uygulandı. Hastalar sonuçlara
göre kontrol, bozulmuş açlık glukozu, bozulmuş glukoz toleransı ve yanlış pozitif glukoz yükleme şeklinde 4 gruba ayrıldı.
Gruplar hematolojik parametreler açısından kıyaslandı.
Bulgular: Ortalama MPV kontrol grubunda diğer gruplara göre anlamlı derecede düşüktü. MPV’nin sensitivitesi, yanlış
pozitif glukoz yükleme (sensitivite: % 70,0; spesifisite: % 55,2; AUC = 0,602; P = 0,029) ve bozulmuş glukoz toleransı
(sensitivite: % 73,1; spesifisite: % 46,1; AUC = 0,621; P = 0,009) durumunu tesbit etmede anlamlı şekilde yüksek iken
bozulmuş açlık glukozunda diğerlerine göre düşüktü (sensitivite: % 60,7; spesifisite: % 58,2; AUC = 0,558; P = 0,374).
Sonuç: Hafif glisemik bozukluğu olan hastalarda MPV seviyesi artmıştır. MPV değerindeki bu artışın gelecekte oluşabilecek
kardiyovasküler hastalık riskinde artışla bir ilgisi olabilir. Bu nedenle bu glisemik bozuklukları olan kadınların, gelecekte
oluşabilecek kardiyovasküler hastalık riskini azaltmak için daha ciddi yöntem ve stratejilerle takip edilmeleri uygun olacaktır.
Anahtar sözcükler: Bozulmuş glukoz toleransı, bozulmuş açlık glukozu, ortalama trombosit hacmi, kardiovasküler hastalık
riski, gebelik
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Introduction

Materials and methods

Impaired glucose tolerance (IGT) and impaired
fasting glucose (IFG) are glycemic disorders and
are considered as prediabetic states (1,2). They are
used to identify individuals at increased risk for
developing diabetes, based on postchallenge or
fasting glucose levels, and are associated with varying
rates of progression to diabetes and differences in
cardiovascular disease (CVD) risk (2).

This study was conducted at Fatih University’s
Department of Obstetrics and Gynecology
between January 2008 and October 2009. Patients
diagnosed with anemia, hemoglobinopathy, chronic
inflammatory disease, renal failure, cyanotic
congenital heart diseases, preexisting or gestational
diabetes mellitus, other chronic diseases, and
preeclampsia were excluded from the study. Informed
consent was obtained from all selected subjects.

There are many studies suggesting that in people
with type 2 diabetes, cardiovascular mortality is
related to the degree of hyperglycemia, and that
total mortality is decreased by lowering blood
glucose (3,4). A similar association is found among
nondiabetic subjects with IFG and IGT. Both IFG
and IGT are associated with a modest increase in
the risk of CVD, with IGT being a slightly stronger
risk predictor (5,6). There is no study in the literature
concerning future CVD risk in pregnant women with
IFG and IGT. The same risks seen in the nonpregnant
population may also be present in pregnant women.
In addition, metabolic changes in pregnancy may
uncover such a risk earlier.
Mean platelet volume (MPV) is a new and
independent risk factor for atherothrombosis and
CVD. Many studies have shown that increased MPV
is a risk factor for myocardial infarction, cerebral
ischaemia, and transient ischaemic attacks (7-9).
The measurement of MPV is an important, simple,
effortless, and cost-effective tool that should be used
for predicting the possibility of impending acute
events (10). Patients with larger platelets can easily be
identified during routine hematological examination
and could possibly benefit from preventive treatment
(11).
In considering gestational diabetes mellitus
(GDM), the consequences of increased perinatal
and maternal morbidity and mortality, in addition to
long-term complications and accurate identification
of precursors of GDM (IGT and IFG), are of the
utmost importance. In this study, we aimed to
compare the platelet count and MPV values (an
elevated MPV level is an independent risk factor for
atherothrombosis and CVD) of pregnant women
with IGT or IFG with those of healthy pregnant
women, to find out whether these glycemic disorders
are risk factors for development of CVD in the future.
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Fasting blood glucose (FBG) was measured and
50 g of oral glucose loading (OGL) was administered
at 24-28 gestational weeks to all participants. FBG
<100 mg/dL and plasma glucose <140 mg/dL after
OGL were accepted as normoglycemia. When plasma
glucose ≥140 mg/dL was measured following the
OGL, a 100-g, 3-h oral glucose tolerance test (OGTT)
was done. GDM was a plasma glucose level of ≥200
mg/dL 1 h after a 50-g OGL, or ≥2 abnormal plasma
glucose values in a 3-h, 100-g OGTT, according to
the American Diabetes Association criteria (≥95 mg/
dL fasting, ≥180 mg/dL at 1 h, ≥155 mg/dL at 2 h, or
≥140 mg/dL at 3 h) (12). Only 1 value abnormality in
the 100-g OGTT was accepted as IGT.
Cases were divided into 4 groups according to
their glycemic status. Cases with normal FBG and
normal OGL were taken as the control group. Cases
with FBG values between 100 and 125 mg/dL and
normal OGL were added to the IFG group. Patients
with normal FBG but high OGL values and 1 value
abnormality in the 100-g OGTT were added to the
IGT group. Pregnant women with normal FBG, high
OGL, and normal OGTT were added to the false
positive OGL group (FP-OGL).
In all cases, systolic and diastolic blood pressures
(BPs) were recorded. Hematologic parameters
(hemoglobin, hematocrit, red blood cell (RBC) and
platelet count, and MPV) were studied. Platelet
counts and MPV measurements were performed as
part of each full blood count. Samples were taken
by antecubital venipuncture into tubes containing
tripotassium EDTA. All samples were analyzed on
a Beckman/Coulter MAXM hematology analyzer
(Beckman Coulter, CA, USA) 2-6 hours after
collection to minimize changes in platelet size. The
MPV reference range was determined as 7.8-11.0
fL. Strict quality control procedures were adopted;
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tri-level controls and external quality assurance
programs were used on a regular basis to ensure the
accuracy and precision of the instrument.
Data were analyzed with SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL, USA). Data were transferred
to computer media. Error control and necessary
corrections were done. Groups were monitored for
conformity to normal distribution by graphical
checks and the Shapiro-Wilk test. Mean ± SD was
used for parameters that were normally distributed.
Median (IQR) was used for groups that were not
distributed normally. To examine the differences
between groups, one-way analysis of variance was
used with the Bonferroni pairwise comparison
of means. The Kruskal-Wallis test, followed by
the Mann-Whitney U-test with the Bonferroni
correction for multiple comparisons, was used for
data that did not fulfill the assumptions required for
analysis of variance. Receiver operating characteristic
(ROC) curve analysis was done to find the sensitivity
and specificity of MPV in the prediction of IFG, FPOGL, IGT, and abnormal OGL results. P ≤ 0.05 was
considered significant.

Results
A total of 222 patients fulfilling the selection criteria
were selected and allocated to 4 groups. These
included 55 control (24.8%), 56 IFG (25.2%), 60 FPOGL (27%), and 51 IGT (23%) cases. The mean age,
gravity, parity, gestational age, systolic and diastolic
BPs, and body mass indexes (BMIs) of the 4 groups
were similar (Table 1).
The mean FBG results were 88.7 ± 8.1 mg/dL,
113.5 ± 5.4 mg/dL, 84.1 ± 7.6 mg/dL, and 97.8 ± 11.4
mg/dL in the control, IFG, FP-OGL, and IGT groups,
respectively. There was a statistically significant
difference between IFG and the other 3 groups. The
FBG was significantly higher in that group. Moreover,
the FBG of the IGT group was significantly higher
than those of the control and FP-OGL groups (Table
1).
The mean OGL results were 106.7 ± 14.8 mg/dL,
124.8 ± 13.4 mg/dL, 158.6 ± 13.8 mg/dL, and 164.7
± 12.7 mg/dL in the control, IFG, FP-OGL, and IGT
groups, respectively (Table 1). There was a significant
difference between the control and the other 3 groups

Table 1. Demographic characteristics, FBG, BP, and OGL results of the groups.
Control

IFG

FP-OGL

IGT

P-value

Age (years)

29.6 ± 4.8

30.1 ± 4.9

29.9 ± 5.4

30.9 ± 6.2

0.612

Gravity (n)

2.0 (IQR = 3)

1.0 (IQR = 1)

2.0 (IQR = 3)

2.0 (IQR = 2)

0.761

Parity (n)

1.0 (IQR = 2)

0.0 (IQR = 1)

1.0 (IQR = 2)

1.0 (IQR = 1)

0.692

G. age (weeks)

25.7 ± 0.3

26.4 ± 0.5

26.1 ± 0.4

25.9 ± 0.5

0.671

BMI (kg/m2)

25.7 ± 5.1

25.5 ± 4.5

25.9 ± 4.9

26.2 ± 5.3

0.524

OGL (mg/dL)

106.7 ± 14.8

124.8 ± 13.4

158.6 ± 13.8

164.7 ± 12.7

<0.001*

FBG (mg/dL)

88.7 ± 8.1

113.5 ± 5.4

84.1 ± 7.6

97.8 ± 11.4

<0.001¶

SBP (mmHg)

90 (IQR = 20)

95 (IQR = 20)

95 (IQR = 15)

90 (IQR = 18.75)

0.492

DBP (mmHg)

60 (IQR = 10)

60 (IQR = 10)

60 (IQR = 13.75)

60 (IQR = 15)

0.876

*Difference between control versus the other 3 groups and between IFG versus IGT and FP-OGL.
¶Difference between IFG and IGT versus the other 3 groups.
IFG: Impaired fasting glucose
FP-OGL: False positive oral glucose loading
IGT: Impaired glucose tolerance
FBG: Fasting blood glucose

IQR: Interquartile range
SBP: Systolic blood pressure
DBP: Diastolic blood pressure
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(P < 0.001). Furthermore, the OGL value of the IFG
group was significantly lower than those of the IGT
and FP-OGL groups (P < 0.001).
When the groups were compared for hematological
parameters, the RBC count, hemoglobin, hematocrit,
red cell distribution width (RDW), and platelet
distribution width (PDW) values were similar (Table
2). The mean platelet counts in the control, IFG,
FP-OGL, and IGT groups were 245.3 ± 68.1, 244.9
± 58.1, 242.4 ± 60.1, and 235.2 ± 57.2 thousand/
mL, respectively. The mean platelet counts were also
similar in all of the groups.
The mean MPV values were 8.4 ± 0.9, 8.9 ± 1.1,
8.9 ± 1.3, and 9.1 ± 1.4 fL in the control, IFG, FPOGL, and IGT groups, respectively. The mean MPV
value was significantly lower in the control group
than in the other 3 groups. Although the MPV value
was higher in the IGT group than in the IFG and FPOGL groups, no significant differences were found
among them (Table 2).
The MPV value had a significantly high sensitivity
in the prediction of the false positive loading test
(sensitivity: 70.0%, specificity: 55.2%, AUC = 0.602,
P = 0.029) and IGT (sensitivity: 73.1%, specificity:
46.1%, AUC = 0.621, P = 0.009), although its
sensitivity was lower than the others in prediction

of IFG (sensitivity: 60.7%, specificity: 58.2%, AUC
= 0.558, P = 0.374). The sensitivity and specificity of
MPV in the prediction of IFG, FP-OGL, and IGT are
shown in Figures 1 and 3 and Table 3.
Discussion
Our results demonstrated that isolated IGT, IFG, and
FP-OGL are associated with increased MPV levels.
The MPV value was higher in the IGT group than in
the FP-OGL and IFG groups, although this difference
between groups was not significant. According to
our results, as glucose intolerance worsens, the MPV
level increases. In other words, the higher the degree
of glucose intolerance, the higher the level of MPV.
These results are important because they indicate the
influence of glucose intolerance on MPV, regardless
of the degree of the intolerance. This increase in
MPV might be associated with an elevated baseline
CVD risk.
A high MPV is an important risk factor for
atherothrombosis, thromboembolism, and CVD (7-10).
A high MPV level alone may not demonstrate a CVD
risk, but it might caution us about CVD risk and the
investigation of other risk factors of CVD. In this way,
present or future CVD risk and possible complications
could be determined and prevented earlier.

Table 2. Hematological findings of the groups.
Control

IFG

FP-OGL

IGT

P-value

Hemoglobin (g/dL)

12.1 ± 1.2

11.9 ± 1.2

12.4 ± 1.4

12.4 ± 0.9

0.614

Hematocrit (%)

35.3 ± 3.4

34.4 ± 3.6

36.2 ± 3.8

35.1 ± 2.8

0.342

245.3 ± 68.1

244.9 ± 58.1

242.4 ± 60.1

235.2 ± 57.2

0.620

Red blood count (×1012/L)

4.2 ± 0.5

4.5 ± 0.5

4.1 ± 0.6

4.2 ± 0.4

0.338

Platelet distribution width (PDW) (%)

16.1 ± 1.5

16.6 ± 1.0

16.4 ± 1.7

16.2 ± 1.5

0.435

Red cell distribution width (RDW) (%)

13.8 ± 2.1

13.5 ± 2.5

13.1 ± 2.0

13.3 ± 1.4

0.335

Mean platelet volume (MPV) (fL)

8.4 ± 0.9

8.9 ± 1.1

8.9 ± 1.3

9.1 ± 1.4

0.029*
0.002¶
0.028‡

Platelets (×109/L)

*Between the control and IFG
¶Between the control and IGT
‡Between the control and FP-OGL
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Table 3. Sensitivity, specificity, AUC, and cut-off value of MPV in prediction of IFG and FP-OGL.
Group

Cut-off MPV (fL)

Sensitivity (%)

Specificity (%)

AUC

P-value

CI

IFG

8.75

60.7

58.2

0.558

0.374

0.437-0.679

FP-OGL

8.45

70.0

55.2

0.602

0.029

0.509-0.695

IGT

8.45

73.1

46.1

0.621

0.009

0.530-0.712

IFG: Impaired fasting glucose
FP-OGL: False positive oral glucose loading
IGT: Impaired glucose tolerance

1.0

1.0

0.8

0.8

0.6

0.6

Sensitivity

Sensitivity

P < 0.05 statistically significant
AUC: Area under the curve
CI: Confidence interval
MPV: Mean platelet value

0.4

0.4

0.2

0.0

0.2

0.0

0.2

0.4
Specificity

0.6

0.8

1.0

0.0

0.0

0.2

0.4
0.6
Specificity

0.8

1.0

Figure 1. Sensitivity and specificity of MPV for IFG.

Figure 2. Sensitivity and specificity of MPV for FP-OGL.

In a collaborative data analysis of 6766 subjects
from 5 Finnish cohorts, it was shown that the survival
profile for coronary heart disease incidence and
CVD mortality was similar for IGT and for newly
diagnosed diabetes, which were worse than that for
IFG (13).

In a similar study done by Coban et al. (16), the
MPV was significantly higher in diabetic and IFG
groups versus the control group. Platelet counts were
not different among the study groups. The MPV and
platelet mass were positively correlated with fasting
glucose and HbA1c in the diabetic and IFG groups.
It has been suggested that subjects with IGT tend
to have increased platelet activation (17). Increased
platelet activity could contribute to increased risk of
cardiovascular disease in IGT and IFG.

The MPV values were higher in diabetic cases,
and with the decrease in blood glucose, a significant
fall was observed in the MPV values (14). In a study
done by Zuberi et al. (15), the MPV values of the
diabetes mellitus (DM), non-DM, and IFG groups
were compared. They observed significant differences
in the MPV levels among all of the groups.

Just like in the nonpregnant population, IFG and
IGT in pregnancy may indicate future CVD risk. No
studies were found in the literature concerning the
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with GDM, IGT, and IFG) would be expected to be
at risk of future CVD. Physicians must be vigilant for
the development of glucose intolerance, especially in
patients with high MPV, and screening for glycemic
disorders might be done in these patients before 24
weeks, if necessary. Therefore, an existing glucose
intolerance could be detected and treated earlier and
possible fetal and maternal complications could be
prevented.

1.0

Sensitivity

0.8

0.6

0.4

0.2

0.0

0.0

0.2

0.4
0.6
Specificity

0.8

1.0

Figure 3. Sensitivity and specificity of MPV for IGT.

future risk of CVD in pregnant women with IGT and
IFG. Glucose intolerance during pregnancy may be
an early sign of metabolic disease later in the life.
Becoming pregnant is a good challenge for women to
assess their metabolic state. Because pregnancy itself
induces excessive metabolic changes, women who
tolerate this changes successfully (healthy pregnant
women) can be accepted as having lower CVD risk
in the future if no other risk factors are present.
Women who tolerate these changes poorly (women

A number of limitations in this study deserve
comment. First, the study groups were quite
modest in size, so it is possible that the study was
underpowered to detect differences among all of the
groups. Second, we only used MPV as a marker of
future CVD. However, other risk factors that can
modify CVD must also be assessed separately. Third,
long-term follow-up of the cases is very important to
correctly stratify the future risk.
Conclusion
Individuals with IFG and IGT that are accepted as
prediabetic and cases of FP-OGL, which is a lesser
degree of glucose intolerance, should be targeted
more aggressively with strategies to lower CVD risk.
A high MPV may be a warning for this. Long-term
studies are necessary to confirm that women with
these glycemic disorders have increased cardiac
morbidity and mortality and to define a potential role
for lifestyle and/or pharmacological intervention.
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